Bio-Rad Laboratories precision oncology assays

Bio-Rad Laboratories is expanding its precision oncology research portfolio with assays and technologies designed to support mutation detection research, liquid biopsy workflows, tumour-informed assay development, molecular residual disease (MRD) research and multiplex biomarker analysis. They will enable researchers to design more powerful multiplex assays and analyse biomarkers with sensitive, absolute quantification — all in scalable, streamlined workflows.

The QX700 ddPCR EGFR Exon 19 Deletions Screening Kit and QX700 ddPCR KRAS G12/G13 Screening Kit have been optimised for use with Bio-Rad’s QX700 ddPCR systems. The assays are intended to support research involving EGFR and KRAS mutations across multiple solid tumour research applications.

Fully compatible across the family of QX systems, the Dark Probe Mutation Detection Assays are additional tools that can help advance translational research in oncology applications, especially for liquid biopsy mutation detection and monitoring in liquid, MRD, liquid biopsy and translational research workflows. Designed to replace the wild-type fluorescent probe in existing ddPCR workflows, quencher-only dark probes suppress wild-type background and free a detection channel. This enables up to four mutation targets to be analysed in a single well, increasing multiplexing capabilities and reducing demand for sample volume.

Finally, 13 oncology-focused ddPLEXCrystalTag ddPCR Assays and CrystalTag Reporters will be available soon. Bio-Rad’s CrystalTag technology separates target recognition from signal generation, enabling flexible assay design and multiplexed detection of up to 21 targets in a single reaction well on the QX700 platform, and supporting efficient development of custom research workflows. These solutions, including assays for mutation detection of the ESR1 mutation, KRAS mutations and HPV, enable high-plex ddPCR research across translational research, biomarker discovery, biopharmaceutical research and advanced multiplex assay development.